Free Trial

SAB Biotherapeutics (SABS) Competitors

SAB Biotherapeutics logo
$1.86 +0.15 (+8.77%)
Closing price 04:00 PM Eastern
Extended Trading
$1.83 -0.03 (-1.61%)
As of 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SABS vs. FBIO, CRIS, BOLT, MTEM, AMGN, GILD, VRTX, REGN, ALNY, and BIIB

Should you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Fortress Biotech (FBIO), Curis (CRIS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "biotechnology" industry.

SAB Biotherapeutics vs.

SAB Biotherapeutics (NASDAQ:SABS) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, community ranking, media sentiment, dividends, risk, profitability and institutional ownership.

7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 26.5% of SAB Biotherapeutics shares are held by insiders. Comparatively, 33.4% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

SAB Biotherapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.

SAB Biotherapeutics currently has a consensus price target of $12.20, indicating a potential upside of 555.91%. Fortress Biotech has a consensus price target of $21.00, indicating a potential upside of 1,113.87%. Given Fortress Biotech's higher possible upside, analysts plainly believe Fortress Biotech is more favorable than SAB Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SAB Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Fortress Biotech
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Fortress Biotech received 295 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 84.62% of users gave SAB Biotherapeutics an outperform vote while only 63.69% of users gave Fortress Biotech an outperform vote.

CompanyUnderperformOutperform
SAB BiotherapeuticsOutperform Votes
33
84.62%
Underperform Votes
6
15.38%
Fortress BiotechOutperform Votes
328
63.69%
Underperform Votes
187
36.31%

In the previous week, SAB Biotherapeutics had 7 more articles in the media than Fortress Biotech. MarketBeat recorded 10 mentions for SAB Biotherapeutics and 3 mentions for Fortress Biotech. SAB Biotherapeutics' average media sentiment score of 0.74 beat Fortress Biotech's score of -0.22 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SAB Biotherapeutics
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Fortress Biotech
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

SAB Biotherapeutics has higher earnings, but lower revenue than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SAB Biotherapeutics$2.24M7.72-$42.19M-$3.70-0.50
Fortress Biotech$57.78M0.89-$60.64M-$2.23-0.78

Fortress Biotech has a net margin of -84.53% compared to SAB Biotherapeutics' net margin of -1,450.14%. Fortress Biotech's return on equity of 0.00% beat SAB Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SAB Biotherapeutics-1,450.14% -94.37% -67.26%
Fortress Biotech -84.53%N/A -34.93%

Summary

Fortress Biotech beats SAB Biotherapeutics on 10 of the 17 factors compared between the two stocks.

Get SAB Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SABS vs. The Competition

MetricSAB BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$17.28M$2.93B$5.33B$8.39B
Dividend YieldN/A1.68%5.21%4.11%
P/E Ratio-0.5031.1826.7119.71
Price / Sales7.72398.76386.13120.55
Price / CashN/A168.6838.2534.62
Price / Book0.303.236.774.50
Net Income-$42.19M-$72.35M$3.23B$248.22M
7 Day Performance-4.12%5.01%1.80%0.56%
1 Month Performance43.08%5.63%11.10%13.17%
1 Year Performance-32.85%-27.04%17.11%7.30%

SAB Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SABS
SAB Biotherapeutics
2.8607 of 5 stars
$1.86
+8.8%
$12.20
+555.9%
-41.2%$17.28M$2.24M-0.50140High Trading Volume
FBIO
Fortress Biotech
1.7116 of 5 stars
$1.76
-2.8%
$21.00
+1,093.2%
-14.1%$52.04M$57.68M-0.58170News Coverage
Analyst Revision
CRIS
Curis
3.0623 of 5 stars
$2.08
+2.5%
$17.00
+717.3%
-82.0%$21.76M$11.20M-0.2760Analyst Forecast
Analyst Revision
BOLT
Bolt Biotherapeutics
3.2561 of 5 stars
$0.33
+11.8%
$1.00
+205.2%
-59.1%$12.56M$7.69M-0.1990Analyst Forecast
MTEM
Molecular Templates
N/AN/AN/AN/A$1,000.00$23.48M0.00260
AMGN
Amgen
4.3727 of 5 stars
$275.85
+1.3%
$310.18
+12.4%
-13.8%$148.33B$34.13B36.5425,200Positive News
Analyst Forecast
GILD
Gilead Sciences
4.6534 of 5 stars
$106.16
+3.6%
$110.55
+4.1%
+60.1%$132.06B$28.74B286.9217,000Positive News
Analyst Forecast
Options Volume
VRTX
Vertex Pharmaceuticals
4.6139 of 5 stars
$440.66
+0.5%
$515.04
+16.9%
-1.5%$112.64B$11.10B-200.304,800Positive News
REGN
Regeneron Pharmaceuticals
4.787 of 5 stars
$596.54
+0.4%
$890.60
+49.3%
-39.2%$64.41B$14.09B15.5811,900Positive News
Dividend Announcement
ALNY
Alnylam Pharmaceuticals
4.1841 of 5 stars
$291.86
+2.3%
$319.17
+9.4%
+95.5%$38.06B$2.35B-134.502,000Positive News
BIIB
Biogen
4.8947 of 5 stars
$129.44
+3.1%
$191.30
+47.8%
-44.3%$18.97B$9.82B11.578,720Analyst Revision

Related Companies and Tools


This page (NASDAQ:SABS) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners